Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SAP-001 in Gout Patients with Hyperuricemia
NCT04040816Phase 2Completed
- Sponsor
- Shanton Pharma
- Start
- Jan 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sap-001 in gout, hyperuricemia, sponsored by Shanton Pharma. Started Jan 2019; status: completed.
02
Drugs
sap-001
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT04040816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04040816.